Table 3.
The association between the tumor burden and the response to anti-PD-1 monotherapy in patients with recurrent or metastatic head and neck cancer.
| N | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| Disease control rate | Disease control rate | ||||||
| HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| BNML | |||||||
| one | 42 | 1.00 | – | – | 1.00 | – | – |
| more | 52 | 2.54 | 1.04–6.22 | 0.042 | 2.81 | 1.10–7.20 | 0.031 |
| BSLD | |||||||
| ≤ 28 | 33 | 1.00 | – | – | 1.00 | – | – |
| > 28 | 61 | 3.57 | 1.29–9.90 | 0.014 | 4.71 | 1.53–14.50 | 0.006 |
| SUVmax | |||||||
| ≤ 12.93 | 23 | 1.00 | – | – | 1.00 | – | – |
| > 12.93 | 25 | 4.28 | 1.16–16.60 | 0.030 | 18.60 | 1.95–178.00 | 0.011 |
Adjusted by age, sex, Eastern Cooperative Oncology Group performance status.
HR hazard ratio, CI confidence interval, BNML the baseline number of metastatic lesions, BSLD the baseline sum of the longest diameters of the target lesions, SUV standardized uptake value.